Neurology and the CNS is the branch of science dealing with anatomy, function, diagnosis and treatment of disorders and disease affecting the central nervous system (brain and spinal cord). Neuroscience medicine includes but is not limited to the study and treatment of Alzheimer’s disease, major depressive disorder, schizophrenia, Parkinson’s disease, epilepsy/seizures, migraine, insomnia/sleep disorders, bipolar disorder, and ADHD.
A neurologist is a medical doctor that specializes in the diagnosis, treatment and management of illnesses affecting the brain, spinal cord, and nervous system. Neurologists must complete at least three years of specialized training in neurology, after completing medical school. A neurosurgeon must go through much more extensive and rigorous schooling and training. On top of diagnosing and treating neurological disorders, neurosurgeons can also perform surgery on the brain, spinal cord, and nerves.
Pharmaceuticals in CNS/Neurology are one of leading fields in medicine in terms of funding and research. On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology. Many of the therapeutic drugs used to treat CNS/Neurological disorders have lost their patent protection or market exclusivity, leading to greater research and market opportunities for competing pharmaceutical and medical device companies. Despite the widespread use of CNS drugs, knowledge of these agents is limited due to the anatomic and neurochemical complexity of the brain and spinal cord.
A neurologist is a medical doctor that specializes in the diagnosis, treatment and management of illnesses affecting the brain, spinal cord, and nervous system. Neurologists must complete at least three years of specialized training in neurology, after completing medical school. A neurosurgeon must go through much more extensive and rigorous schooling and training. On top of diagnosing and treating neurological disorders, neurosurgeons can also perform surgery on the brain, spinal cord, and nerves.
Pharmaceuticals in CNS/Neurology are one of leading fields in medicine in terms of funding and research. On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology. Many of the therapeutic drugs used to treat CNS/Neurological disorders have lost their patent protection or market exclusivity, leading to greater research and market opportunities for competing pharmaceutical and medical device companies. Despite the widespread use of CNS drugs, knowledge of these agents is limited due to the anatomic and neurochemical complexity of the brain and spinal cord.
All reports in CNS/Neurology
|
Brain Hemorrhage Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... and data relating to the clinical trials on Brain Hemorrhage. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...
|
more...
|
$1,000.00
|
|
Brain Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... and data relating to the clinical trials on Brain Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...
|
more...
|
$1,000.00
|
|
Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... scenario. This report provides elemental information and data relating to the clinical trials on Cerebral Infarction (Brain Infarction). It includes an overview of the trial numbers and their recruitment status as per the site of ...
|
more...
|
$1,000.00
|
|
Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... information and data relating to the clinical trials on Cluster Headache. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...
|
more...
|
$1,000.00
|
|
Tension -Type Headache Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... provides elemental information and data relating to the clinical trials on Tension -Type Headache. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ...
|
more...
|
$1,000.00
|
|
Traumatic Brain Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... provides elemental information and data relating to the clinical trials on Traumatic Brain Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ...
|
more...
|
$1,000.00
|
|
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... provides elemental information and data relating to the clinical trials on Amyotrophic Lateral Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ...
|
more...
|
$1,000.00
|
|
Brain Ischemia Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
... and data relating to the clinical trials on Brain Ischemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...
|
more...
|
$1,000.00
|
|
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
4/2/2012 | published by: GBI Research
... its latest research “Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment”, which provides insights into the CNS orphan ...
|
more...
|
$3,500.00
|
|
Mild Cognitive Impairment Global Clinical Trials Review, H1, 2012
3/31/2012 | published by: GlobalData
... provides elemental information and data relating to the clinical trials on Mild Cognitive Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ...
|
more...
|
$1,000.00
|
|
Opium (Opioid) Addiction – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Opium (Opioid) Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction. 'Opium (Opioid) ...
|
more...
|
$500.00
|
|
Brain Hemorrhage – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Brain Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Hemorrhage. 'Brain Hemorrhage - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Psychosis – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis . 'Psychosis - Pipeline Review, H1 2012' is built using data ...
|
more...
|
$500.00
|
|
Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2/29/2012 | published by: GlobalData
... essential source of information and analysis on the global Narcolepsy Therapeutics market. The report identifies the key trends shaping and driving the global Narcolepsy Therapeutics market. The report also provides insights on the prevalent competitive ...
|
more...
|
$3,995.00
|
|
Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2/29/2012 | published by: GlobalData
... is an essential source of information and analysis on the global Tourette Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Tourette Syndrome Therapeutics market. The report also provides insights ...
|
more...
|
$3,995.00
|
|
Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2/29/2012 | published by: GlobalData
... is an essential source of information and analysis on the global Childhood Epilepsy Therapeutics market. The report identifies the key trends shaping and driving the global Childhood Epilepsy Therapeutics market. The report also provides insights ...
|
more...
|
$3,995.00
|
|
Panic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2/29/2012 | published by: GlobalData
... is an essential source of information and analysis on the global Panic Disorder Therapeutics market. The report identifies the key trends shaping and driving the global Panic Disorder Therapeutics market. The report also provides insights ...
|
more...
|
$3,995.00
|
|
Schizophrenia – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. 'Schizophrenia - Pipeline Review, H1 2012' is built using data and information ...
|
more...
|
$500.00
|
|
Epilepsy – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. 'Epilepsy - Pipeline Review, H1 2012' is built using data and information ...
|
more...
|
$500.00
|
|
Major Depressive Disorder – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... the therapeutic development for Major Depressive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Major Depressive Disorder. 'Major Depressive ...
|
more...
|
$500.00
|
|
Migraine – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. 'Migraine - Pipeline Review, H1 2012' is built using data and information ...
|
more...
|
$500.00
|
|
Autism – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autism. 'Autism - Pipeline Review, H1 2012' is built using data and information ...
|
more...
|
$500.00
|
|
Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... provides information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bipolar ...
|
more...
|
$500.00
|
|
Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. 'Amyotrophic Lateral ...
|
more...
|
$500.00
|
|
Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the ...
|
more...
|
$500.00
|


